Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: Data from the Heart and Soul study

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 604-610

  Zhang, Mary H ^a   Na, Beeya ^b   Schiller, Nelson B ^c   Whooley, Mary A ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coronary heart disease (CHD); Exercise capacity; Inflammation; Ischemia; Resistin

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; EXERCISE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC EQUIVALENT; PRIORITY JOURNAL; RISK; STRESS ECHOCARDIOGRAPHY; TREADMILL EXERCISE;

AGED; C-REACTIVE PROTEIN; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, STRESS; EXERCISE TEST; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RESISTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649738522     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.015     Document Type: Article

References (37)

1. Shuldiner A.R., Yang R., Gong D.W. Resistin, obesity and insulin resistance-the emerging role of the adipocyte as an endocrine organ. N Engl J Med 2001, 345:1345-1346.
2. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
3. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472-476.
4. Yang R.Z., Huang Q., Xu A., et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003, 310:927-935.
5. Reilly M.P., Lehrke M., Wolfe M.L., et al. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
6. Burnett M.S., Devaney J.M., Adenika R.J., et al. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006, 91:64-68.
7. Lee J.H., Chan J.L., Yiannakouris N., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
8. Fargnoli J.L., Sun Q., Olenczuk D., et al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2000, 162:281-288.
9. Kaser S., Kaser A., Sandhofer A., et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309:286-290.
10. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003, 108:736-740.
11. Burnett M.S., Lee C.W., Kinnaird T.D., et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241-248.
12. Rothwell S.E., Richards A.M., Pemberton C.J. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006, 349:400-407.
13. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
14. Azuma K., Katsukawa F., Oguchi S., et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003, 11:997-1001.
15. Fujinami A., Obayashi H., Ohta K., et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004, 339:57-63.
16. Ohmori R., Momiyama Y., Kato R., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379-380.
17. Yaturu S., Daberry R.P., Rains J., Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006, 34:219-223.
18. Beattie M.S., Shlipak M.G., Liu H., et al. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul study. Circulation 2003, 107:245-250.
19. Gehi A.K., Ali S., Na B., et al. Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2008, 168:1423-1428.
20. Gibbons R.J., Balady G.J., Bricker J.T., et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002, 106:1883-1892.
21. Myers J., Prakash M., Froelicher V., et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002, 346:793-801.
22. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
23. Pischon T., Bamberger C.M., Kratzsch J., et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764-1771.
24. Diez J.J., Iglesias P., Fernandez-Reyes M.J., et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005, 62:242-249.
25. Kielstein J.T., Becker B., Graf S., et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003, 42:62-66.
26. Mora S., Redberg R.F., Cui Y., et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003, 290:1600-1607.
27. Krivokapich J., Child J.S., Gerber R.S., et al. Prognostic usefulness of positive or negative exercise stress echocardiography for predicting coronary events in ensuing twelve months. Am J Cardiol 1993, 71:646-651.
28. McCully R.B., Roger V.L., Ommen S.R., et al. Outcomes of patients with reduced exercise capacity at time of exercise echocardiography. Mayo Clin Proc 2004, 79:750-757.
29. McCully R.B., Roger V.L., Mahoney D.W., et al. Outcome after abnormal exercise echocardiography for patients with good exercise capacity: prognostic importance of the extent and severity of exercise-related left ventricular dysfunction. J Am Coll Cardiol 2002, 39:1345-1352.
30. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
31. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
32. Gulati M., Black H.R., Shaw L.J., et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med 2005, 353:468-475.
33. Morris C.K., Myers J., Froelicher V.F., et al. Nomogram based on metabolic equivalents and age for assessing aerobic exercise capacity in men. J Am Coll Cardiol 1993, 22:175-182.
34. Grimble R.F. Inflammatory response in the elderly. Curr Opin Clin Nutr Metab Care 2003, 6:21-29.
35. Savage D.B., Sewter C.P., Klenk E.S., et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001, 50:2199-2202.
36. Samaha F.F., Szapary P.O., Iqbal N., et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006, 26:624-630.
37. Aquilante C.L., Kosmiski L.A., Zineh I., et al. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy 2010, 30:236-247.